TY  - JOUR
A1  - Prelog, Martina
T1  - Vaccination in Patients with Rheumatoid Arthritis Receiving Immunotherapies
JF  - Clinical & Cellular Immunology
N2  - Patients with rheumatoid arthritis (RA) are at higher risk to suffer from morbidity due to vaccine-preventable diseases and, thus, display an important target population to receive vaccines for protection from infectious complications. There have been only a few studies focusing on the administration of vaccines in RA patients with immunotherapy. Overall, antibody response rates against influenza or pneumococcal disease appeared to be only slightly lower than expected in healthy individuals. Crucial problems in the interpretation of data from studies in RA patients vaccinated against influenza and pneumococcal disease are the impaired comparability of studies due to different study designs and type of vaccines used, different health states among RA patients, heterogeneity in treatments including concomitant therapy with conventional DMARDs and glucocorticoids in addition to biological agents. Assessment of vaccination status should be performed in the initial work-up of patients with RA and should ideally be administered before initiation of immunotherapies or during stable disease. Due to differences in antibody responses and uncertainty regarding maintenance of protective antibodies, routine controls for antibody titers and specific strategies for earlier re-vaccination might be scheduled for patients with RA.
KW  - Immunotherapy
KW  - Anti-TNF-alpha agents
KW  - Rituximab
KW  - Tocilizumab
KW  - Abatacept
KW  - Pneumococcal vaccination
KW  - Influenza vaccination
Y1  - 2013
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-96446
ER  - 
TY  - JOUR
A1  - Kraemer, Markus
A1  - Becker, Jana
A1  - Bley, Thorsten Alexander
A1  - Steinbrecher, Andreas
A1  - Minnerup, Jens
A1  - Hellmich, Bernhard
T1  - Diagnostik und Therapie der Riesenzellarteriitis
T1  - Diagnostics and treatment of giant cell arteritis
JF  - Der Nervenarzt
N2  - Die Riesenzellarteriitis (RZA) ist in der Altersgruppe der über 50-Jährigen die häufigste idiopathische systemische Vaskulitis. Die Erkrankung bedarf einer zeitnahen Diagnostik und Therapie, um schwere Komplikationen wie eine Erblindung oder einen Schlaganfall zu vermeiden. Die Rezidivneigung erfordert eine mehrjährige, zum Teil lebenslange Glukokortikoid(GC)-Therapie, was das Risiko GC-induzierter Langzeitnebenwirkungen erhöht. Daher wird bei der Mehrzahl der Patienten eine additive GC-einsparende Therapie empfohlen. Hierzu steht der Anti-IL-6-Rezeptor-Antikörper Tocilizumab in subkutaner Applikation als zugelassene Substanz zur Verfügung, alternativ kann Methotrexat (MTX) eingesetzt werden (off-label).
N2  - Giant cell arteritis (GCA) is the most common idiopathic systemic vasculitis in the age group over 50 years. It requires prompt diagnostics and treatment to avoid severe complications, such as visual loss or stroke. The tendency to relapse makes a glucocorticoid (GC) treatment necessary for several years and sometimes lifelong, which increases the risk of GC-induced long-term side effects. Therefore, additive GC-sparing treatment is recommended in the majority of patients. For this purpose, the anti-IL‑6 receptor antibody tocilizumab is available as an approved substance for subcutaneous application; alternatively, methotrexate (MTX) can be used (off-label).
KW  - Riesenzellarteriitis
KW  - Diagnose
KW  - Therapie
KW  - Glukokortikoide
KW  - Glukokortikoideinsparende Therapie
KW  - Tocilizumab
KW  - Methotrexat
KW  - giant cell arteritis
KW  - diagnosis
KW  - therapy
KW  - glucocorticoids
KW  - glucocorticoid-sparing agents
KW  - Tocilizumab
KW  - Methotrexate
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-307771
SN  - 0028-2804
SN  - 1433-0407
VL  - 93
IS  - 8
ER  -